• Citer

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

par Baselga, José;Bradbury, Ian;Eidtmann, Holger;Di Cosimo, Serena;de Azambuja, Evandro ;Aura, Claudia;Gomez, Henry;Dinh, Phuong ;Fauria, Karine;van Dooren, Veerle;Aktan, Gursel;Goldhirsch, Aron;Chang, Tsai-Wang;Horváth, Zsolt;Coccia-Portugal, Maria;Domont, Julien;Tseng, Ling-Min;Kunz, Georg;Sohn, Joo Hyuk;Semiglazov, Vladimir;Lerzo, Guillermo;Palacova, Marketa;Probachai, Volodymyr;Pusztai, Lajos;Untch, Michael;Gelber, Richard;Piccart-Gebhart, Martine ;NeoALTTO Study Team,
Référence Lancet, 379, 9816, page (633-640)
Publication Publié, 2012-02

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
Auteur:	Baselga, José; Bradbury, Ian; Eidtmann, Holger; Di Cosimo, Serena; de Azambuja, Evandro; Aura, Claudia; Gomez, Henry; Dinh, Phuong; Fauria, Karine; van Dooren, Veerle; Aktan, Gursel; Goldhirsch, Aron; Chang, Tsai-Wang; Horváth, Zsolt; Coccia-Portugal, Maria; Domont, Julien; Tseng, Ling-Min; Kunz, Georg; Sohn, Joo Hyuk; Semiglazov, Vladimir; Lerzo, Guillermo; Palacova, Marketa; Probachai, Volodymyr; Pusztai, Lajos; Untch, Michael; Gelber, Richard; Piccart-Gebhart, Martine; NeoALTTO Study Team,
Informations sur la publication:	Lancet, 379, 9816, page (633-640)
Statut de publication:	Publié, 2012-02
Sujet CREF:	Cancérologie
MeSH keywords:	Administration, Oral
	Adult
	Aged
	Antibodies, Monoclonal, Humanized -- administration & dosage -- adverse effects
	Antineoplastic Combined Chemotherapy Protocols -- adverse effects -- therapeutic use
	Breast Neoplasms -- chemistry -- drug therapy -- pathology -- surgery
	Chemotherapy, Adjuvant
	Diarrhea -- chemically induced
	Drug Administration Schedule
	Female
	Humans
	Infusions, Intravenous
	Liver -- drug effects -- metabolism
	Middle Aged
	Neoadjuvant Therapy -- methods
	Paclitaxel -- administration & dosage -- adverse effects
	Quinazolines -- administration & dosage -- adverse effects
	Receptor, erbB-2 -- analysis -- antagonists & inhibitors
	Treatment Outcome
	Tumor Markers, Biological -- analysis -- antagonists & inhibitors
Note générale:	Clinical Trial, Phase III
	Journal Article
	Multicenter Study
	Randomized Controlled Trial
	Research Support, Non-U.S. Gov't
	SCOPUS: cp.j
Langue:	Anglais
Identificateurs:	urn:issn:0140-6736
	info:doi/10.1016/S0140-6736(11)61847-3
	info:pii/S0140-6736(11)61847-3
	info:scp/84857236823
	info:pmid/22257673